Login to Your Account

U.K. cancer drug fund a costly but not rational approach, study shows

By Nuala Moran
Staff Writer

Friday, April 28, 2017

LONDON – The majority of drugs paid for by a fund set up to provide access to the new wave of expensive cancer therapies failed to show any evidence of meaningful clinical benefit and may have resulted in patients suffering unnecessarily from toxic side effects.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription